Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 8/20 | 0.45 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PRKDC | P78527 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
| ▸ | CTSE | P14091 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL280762 | 0.81 | SCN9A (0.42) | SCN9ABACE1KDM4EPKMUTS2R | |
| SCHEMBL328310 | 0.73 | SCN9A (0.42) | SCN9ABACE1KDM4EPKMUTS2R | |
| SCHEMBL2306217 | 0.72 | SCN9A (0.55) | SCN9ABACE1KDM4EPKMGPR119 | |
| SCHEMBL2307297 | 0.71 | SCN9A (0.48) | SCN9ABACE1KDM4EPKMGPR119 | |
| SCHEMBL10267012 | 0.71 | SCN9A (0.54) | SCN9ABACE1KDM4EPKM | |
| SCHEMBL284065 | 0.71 | SCN9A (0.44) | SCN9ABACE1KDM4EPKMUTS2R | |
| SCHEMBL281917 | 0.70 | TP53 (0.39) | SCN9ABACE1GPR119 | |
| SCHEMBL281544 | 0.69 | SCN9A (0.45) | SCN9ABACE1KDM4EPKMGPR119 | |
| SCHEMBL10258994 | 0.68 | GPR119 (0.39) | SCN9ABACE1UTS2RPIK3CAGPR119 | |
| SCHEMBL7396423 | 0.67 | KDM4E (0.53) | BACE1KDM4EPKMUTS2RGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294842-A9 | SPIRO (FURO [3, 2-C] PYRIDINE-3-3' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN | XENON PHARMACEUTICALS INC. (CA) | 2011-12-01 | — | — | US | claimed |
| US-20100160362-A1 | SPIRO (FURO [3, 2-C] PYRIDINE-3-3' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN | XENON PHARMACEUTICALS INC. (CA) | 2010-06-24 | — | — | US | claimed |
| US-20110294842-A9 | SPIRO (FURO [3, 2-C] PYRIDINE-3-3' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN | XENON PHARMACEUTICALS INC. (CA) | 2011-12-01 | — | — | US | disclosed |
| US-20110294842-A9 | SPIRO (FURO [3, 2-C] PYRIDINE-3-3' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN | XENON PHARMACEUTICALS INC. (CA) | 2011-12-01 | — | — | US | disclosed |
| US-20110294842-A9 | SPIRO (FURO [3, 2-C] PYRIDINE-3-3' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN | XENON PHARMACEUTICALS INC. (CA) | 2011-12-01 | — | — | US | disclosed |
| US-20100160362-A1 | SPIRO (FURO [3, 2-C] PYRIDINE-3-3' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN | XENON PHARMACEUTICALS INC. (CA) | 2010-06-24 | — | — | US | disclosed |
| US-20100160362-A1 | SPIRO (FURO [3, 2-C] PYRIDINE-3-3' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN | XENON PHARMACEUTICALS INC. (CA) | 2010-06-24 | — | — | US | disclosed |
| US-20100160362-A1 | SPIRO (FURO [3, 2-C] PYRIDINE-3-3' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN | XENON PHARMACEUTICALS INC. (CA) | 2010-06-24 | — | — | US | disclosed |
| WO-2008046049-A1 | SPIRO (FURO [3, 2-C] PYRIDINE-3-3 ' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN | XENON PHARMACEUTICALS INC. (CA) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160362-A1 | SPIRO (FURO [3, 2-C] PYRIDINE-3-3' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN | SCN3A, SCN1B, SCN2B | SCN9A 38/4885BACE1 2844/4885KDM4E 3441/4885 |
| US-20110294842-A9 | SPIRO (FURO [3, 2-C] PYRIDINE-3-3' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN | SCN3A, SCN1B, SCN2B | SCN9A 38/4885BACE1 2844/4885KDM4E 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.